iHuman Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IH research report →
Price Chart
About the company
Operating within the People's Republic of China, iHuman Inc. specializes in delivering educational resources aimed at fostering cognitive growth. Their offerings reach a broad audience, encompassing individual consumers, early learning institutions, and wholesale distributors.
- CEO
- Peng Dai
- IPO
- 2020
- Employees
- 558
- HQ
- Beijing, BE, CN
Get TickerSpark's AI analysis on IH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.78M
- P/E
- 3.29
- PEG
- -0.04
- P/S
- 0.10
- P/B
- 0.09
- EV/EBITDA
- -79.05
- Div Yield
- 7.39%
- Gross Margin
- 66.63%
- Op Margin
- -0.69%
- Net Margin
- 3.18%
- ROE
- 2.54%
- ROIC
- -0.60%
Latest fiscal year · YoY change
- Revenue
- $807.02M-12.5%
- Gross Profit
- $547.61M-14.5%
- Op Income
- $66.76M
- Net Income
- $95.40M-3.2%
- EPS
- $9.10-3.2%
- OCF Growth
- -14.7%
- FCF Growth
- -11.6%
- 52W High
- $3.08
- 52W Low
- $1.10
- 50D MA
- $1.24
- 200D MA
- $1.59
- Beta
- 0.13
- RSI (14)
- 44
- Avg Volume
- 6.90K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
iHuman delivered a very strong Q1 with revenue up 191% year over year, record user metrics, and profitability improving as the company leaned into product-led growth and new AI/reading products.· June 8, 2021
- Q1 revenue rose 191% year over year to RMB227 million, led by learning services revenue of RMB192 million, up 233%.
- Average total MAUs reached 16.5 million, up 97% year over year, and paying users hit a record 1.68 million.
- Gross profit was RMB161 million and gross margin improved to 71% from 66% a year ago.
- Operating income turned positive at RMB3.6 million, and net income was RMB7.1 million versus a net loss last year.
- Management guided Q2 revenue to RMB217 million-RMB227 million, implying 102%-111% year-over-year growth.
Q1 2021 total revenues increased 191% year over year to RMB227 million. Learning services revenue rose 233% year over year to RMB192 million, while learning material and devices revenue was RMB35 million, up 71%. Gross profit was RMB161 million, up 212% year over year, and gross margin was 71% versus 66% in the prior-year quarter. Operating income was RMB3.6 million versus an operating loss of RMB2.5 million a year ago; net income was RMB7.1 million versus a net loss of RMB1.6 million, and basic/diluted EPS for ADS was $0.13 versus a loss of $0.11. Cash and cash equivalents were RMB841 million, deferred revenue and customer advances were RMB318 million, and the company said it has no debt. For Q2, management expects total revenue of RMB217 million-RMB227 million, up 102%-111% year over year, noting Q2 is normally a slow season.
CEO Peng Dai framed the quarter as evidence that iHuman is strengthening its position in childhood edutainment, citing rapid user adoption and strong feedback from parents and children. His focus was on product differentiation: interactive, child-centered content, AI-enabled learning, and a growing pipeline that includes iHuman Chinese Reading, iHuman Readers with Oxford University Press, and iHumanpedia. His tone was optimistic and expansionary, emphasizing long-term sustainable growth, product innovation, and broadening the portfolio beyond the current core apps.
CFO Vivian Wang highlighted the hard numbers: Q1 revenue of RMB227 million, gross profit of RMB161 million, gross margin of 71%, operating income of RMB3.6 million, and net income of RMB7.1 million. She also noted the company’s balance sheet strength, with RMB841 million in cash and cash equivalents and no debt, while deferred revenue and customer advances rose to RMB318 million. On spending, she pointed to elevated R&D at RMB82 million, sales and marketing at RMB53 million, and G&A at RMB23 million, and said R&D investment and headcount are expected to increase further.
Analysts focused on the new AI reading product, regulatory risk, product differentiation, R&D spending, headcount plans, and traffic acquisition. Management said iHuman Chinese Reading had trial runs starting in April, with conversion better than expected and first-month completion rates described as as high as the high 90%s; it also said the product will be expanded with more features and content. On regulation, management argued the company’s edutainment-focused, low-pressure, word-of-mouth-driven model aligns with policy priorities, and on acquisition it said product quality, app store rankings, and offline-online channel synergies are the main drivers rather than heavy paid acquisition.
The call showed strong momentum in both revenue and engagement, with record MAUs, record paying users, and improving margins despite heavy growth investment. Management also sounded confident that new products such as Oxford-based reading apps, AI Chinese reading, and STEM content can deepen differentiation and support future growth.
The company is still spending aggressively on R&D, marketing, and hiring, so expense growth remains high even as revenue scales. Management also acknowledged regulatory scrutiny in after-school tutoring and said Q2 is normally a slow season, which is why it guided only to a similar revenue range as Q1 rather than assuming sequential acceleration.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.9%
- Shares Outstanding
- 10.24M
- Float Shares
- 10.13M
Held by 23 ETFs
Biggest fund positions in IH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Lin Congyu | other | 0 |
| Jun 29, 26 | Li Teng | other | 0 |
| Mar 18, 26 | Lu Wenbin | other | 0 |
| Mar 18, 26 | Hayes Wendy W. | other | 53,000 |
| Mar 18, 26 | Dai Peng | other | 0 |
| Mar 18, 26 | Chi Yufeng | other | 0 |
| Mar 18, 26 | Chi Hanfeng | other | 27,000 |
| Mar 18, 26 | Li Xuenan | other | 27,000 |
| Mar 18, 26 | Wang Weiwei | other | 0 |
| Mar 18, 26 | Wang Weiwei | other | 520,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IH coverage
Recent articles, reports, and earnings notes.
No research on IH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IH report →Head-To-Head Contrast: IMAX (NYSE:IMAX) versus iHuman (NYSE:IH)
defenseworld.net · Oct 5
iHuman Inc. Announces Second Quarter 2026 Unaudited Financial Results
prnewswire.com · Sep 29
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
gurufocus.com · Sep 9
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
gurufocus.com · Aug 24
iHuman Inc. Announces First Quarter 2026 Unaudited Financial Results
prnewswire.com · Jun 29
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
prnewswire.com · Jun 16
iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
gurufocus.com · May 31
iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
prnewswire.com · May 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.